Title:
HIGH-EFFICIENCY METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS
Document Type and Number:
WIPO Patent Application WO/2020/085480
Kind Code:
A1
Abstract:
The purpose of the present invention is to improve efficiency in a method for producing chimeric antigen receptor (CAR)-expressing cells. Provided is a method for producing genetically modified mammalian cells, the method comprising: a) a step of introducing, by a transposon method, a polynucleotide coding for a chimeric antigen receptor (CAR) protein into a cell population that contains T-cells derived from a mammal to obtain a genetically modified cell population; b) a step of preparing an endogenous cell population derived from the mammal that expresses a protein that binds to the CAR; and c) a step of coculturing the genetically modified cell population of step a) and the endogenous cell population of step b).
More Like This:
| JP2008504236 | FGFR binding peptide |
| JP2010526029 | FXYD5 regulator for treating, diagnosing, and detecting cancer |
| JP2014058523 | T CELL REGULATION METHOD |
Inventors:
NAKAZAWA YOZO (JP)
TANAKA MIYUKI (JP)
MOROKAWA HIROKAZU (JP)
NARIMATSU SHOGO (JP)
TANAKA MIYUKI (JP)
MOROKAWA HIROKAZU (JP)
NARIMATSU SHOGO (JP)
Application Number:
PCT/JP2019/041878
Publication Date:
April 30, 2020
Filing Date:
October 25, 2019
Export Citation:
Assignee:
KISSEI PHARMACEUTICAL (JP)
UNIV SHINSHU (JP)
UNIV SHINSHU (JP)
International Classes:
C07K14/705; C12N5/0783; C12N5/10; C12N15/12; C12N15/63
Domestic Patent References:
| WO2017061615A1 | 2017-04-13 | |||
| WO2017079705A1 | 2017-05-11 | |||
| WO2017061615A1 | 2017-04-13 |
Foreign References:
| JP2018531014A | 2018-10-25 | |||
| JP2013529061A | 2013-07-18 | |||
| US5827642A | 1998-10-27 | |||
| JP2018202336A | 2018-12-27 |
Other References:
N. ENGL. J. MED., vol. 377, 2017, pages 2531 - 2544
N. ENGL. J. MED., vol. 378, 2018, pages 439 - 448
J IMMUNOTHERAPY, vol. 36, no. 1, 2013, pages 1 - 2
CURRENT OPINION IN BIOTECHNOLOGY, vol. 53, 2018, pages 164 - 181
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 1269
LANCET, vol. 385, 2015, pages 517 - 528
J IMMUNOL METHODS, vol. 275, no. 1-2, pages 251 - 5
HUMAN GENE THERAPY, vol. 21, 2010, pages 427 - 437
MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 3, 2018, pages 131 - 140
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
HUANG XGUO H ET AL., MOL THER., vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES., vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER, vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL THER, vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL REV, vol. 257, 2014, pages 181 - 90
MAITI SNHULS H ET AL., J IMMUNOTHER, vol. 36, 2013, pages 112 - 23
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER., vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL THER., vol. 19, 2011, pages 2239 - 48
SAHA SNAKAZAWA Y ET AL.: "69", J VIS EXP., 2012, pages e4235
NAKAZAWA YSAHA S ET AL., J IMMUNOTHER., vol. 36, 2013, pages 3 - 10
NAKAZAWA ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, 2016, pages 27
ZOLA H. ET AL., IMMUNOL CELL BIOL, vol. 69, 1991, pages 41 l - 412
SAVOLDO ET AL., J CLIN INVEST, vol. 121, no. 5, 2011, pages 1822 - 1826
HUYE ET AL., MOL THER, vol. 19, no. 12, 2011, pages 2239 - 2248
See also references of EP 3872087A4
N. ENGL. J. MED., vol. 378, 2018, pages 439 - 448
J IMMUNOTHERAPY, vol. 36, no. 1, 2013, pages 1 - 2
CURRENT OPINION IN BIOTECHNOLOGY, vol. 53, 2018, pages 164 - 181
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 1269
LANCET, vol. 385, 2015, pages 517 - 528
J IMMUNOL METHODS, vol. 275, no. 1-2, pages 251 - 5
HUMAN GENE THERAPY, vol. 21, 2010, pages 427 - 437
MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT, vol. 3, 2018, pages 131 - 140
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
HUANG XGUO H ET AL., MOL THER., vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES., vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER, vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL THER, vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL REV, vol. 257, 2014, pages 181 - 90
MAITI SNHULS H ET AL., J IMMUNOTHER, vol. 36, 2013, pages 112 - 23
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER., vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL THER., vol. 19, 2011, pages 2239 - 48
SAHA SNAKAZAWA Y ET AL.: "69", J VIS EXP., 2012, pages e4235
NAKAZAWA YSAHA S ET AL., J IMMUNOTHER., vol. 36, 2013, pages 3 - 10
NAKAZAWA ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 9, 2016, pages 27
ZOLA H. ET AL., IMMUNOL CELL BIOL, vol. 69, 1991, pages 41 l - 412
SAVOLDO ET AL., J CLIN INVEST, vol. 121, no. 5, 2011, pages 1822 - 1826
HUYE ET AL., MOL THER, vol. 19, no. 12, 2011, pages 2239 - 2248
See also references of EP 3872087A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF:
Previous Patent: FINE FIBROUS CELLULOSE-CONTAINING COMPOSITION AND METHOD FOR MANUFACTURING SAME
Next Patent: FITTING STRUCTURE
Next Patent: FITTING STRUCTURE